Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."

This study is aimed at developing a Nanoemulsion formulation of a poorly water-soluble and thermally, oxidatively, and photolytically unstable active pharmaceutical ingredient (API) for ophthalmic application, specifically for the reduction of intraocular pressure (IOP) and to provide neuroprotection.

This discussion focuses on the challenges of global drug development and the long-term implications of COVID-19.